These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 37986208)

  • 1. Genomic and Molecular Characteristics of Ovarian Carcinosarcoma.
    Ramphal K; Hadfield MJ; Bandera CM; Hart J; Dizon DS
    Am J Clin Oncol; 2023 Dec; 46(12):572-576. PubMed ID: 37986208
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Homologous recombination deficiency (HRD) signature-3 in ovarian and uterine carcinosarcomas correlates with preclinical sensitivity to Olaparib, a poly (adenosine diphosphate [ADP]- ribose) polymerase (PARP) inhibitor.
    Tymon-Rosario JR; Manara P; Manavella DD; Bellone S; Hartwich TMP; Harold J; Yang-Hartwich Y; Zipponi M; Choi J; Jeong K; Mutlu L; Yang K; Altwerger G; Menderes G; Ratner E; Huang GS; Clark M; Andikyan V; Azodi M; Schwartz PE; Alexandrov LB; Santin AD
    Gynecol Oncol; 2022 Jul; 166(1):117-125. PubMed ID: 35599167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. "Carcinosarcoma of the ovary, fallopian tube, and peritoneum: Prognostic factors and treatment modalities".
    Rauh-Hain JA; Birrer M; Del Carmen MG
    Gynecol Oncol; 2016 Aug; 142(2):248-54. PubMed ID: 27321238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Defective DNA repair in hereditary ovarian cancers: Implications for therapy.
    Burgess BT; Kolesar JM
    Am J Health Syst Pharm; 2018 Nov; 75(21):1697-1707. PubMed ID: 30228165
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epithelial-to-Mesenchymal Transition Supports Ovarian Carcinosarcoma Tumorigenesis and Confers Sensitivity to Microtubule Targeting with Eribulin.
    Ho GY; Kyran EL; Bedo J; Wakefield MJ; Ennis DP; Mirza HB; Vandenberg CJ; Lieschke E; Farrell A; Hadla A; Lim R; Dall G; Vince JE; Chua NK; Kondrashova O; Upstill-Goddard R; Bailey UM; Dowson S; Roxburgh P; Glasspool RM; Bryson G; Biankin AV; ; Cooke SL; Ratnayake G; McNally O; Traficante N; ; DeFazio A; Weroha SJ; Bowtell DD; McNeish IA; Papenfuss AT; Scott CL; Barker HE
    Cancer Res; 2022 Dec; 82(23):4457-4473. PubMed ID: 36206301
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An update on current and emerging therapies for epithelial ovarian cancer: Focus on poly(adenosine diphosphate-ribose) polymerase inhibition and antiangiogenesis.
    Chung C; Lee R
    J Oncol Pharm Pract; 2017 Sep; 23(6):454-469. PubMed ID: 27357817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Update on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatment.
    Papa A; Caruso D; Strudel M; Tomao S; Tomao F
    J Transl Med; 2016 Sep; 14():267. PubMed ID: 27634150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Frontiers of Ovarian Carcinosarcoma.
    Ismail A; Choi S; Boussios S
    Curr Treat Options Oncol; 2023 Dec; 24(12):1667-1682. PubMed ID: 37938504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Carcinosarcoma of the ovary: a review of the literature.
    del Carmen MG; Birrer M; Schorge JO
    Gynecol Oncol; 2012 Apr; 125(1):271-7. PubMed ID: 22155675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinicopathological and molecular features of tubo-ovarian carcinosarcomas: a series of 51 cases.
    Liang F; Shi Y; Chen Y; Tao X; Ding J
    Front Oncol; 2024; 14():1427154. PubMed ID: 39239274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conventional chemotherapy and oncogenic pathway targeting in ovarian carcinosarcoma using a patient-derived tumorgraft.
    Glaser G; Weroha SJ; Becker MA; Hou X; Enderica-Gonzalez S; Harrington SC; Haluska P
    PLoS One; 2015; 10(5):e0126867. PubMed ID: 25962155
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized, two-arm, noncomparative phase 2 study of olaparib plus cediranib or durvalumab in HRR-mutated, platinum-resistant ovarian cancer: A substudy of KGOG 3045.
    Kim YN; Joung JG; Park E; Kim JW; Lee JB; Lim J; Kim S; Choi CH; Kim HS; Chung J; Kim BG; Lee JY
    Int J Cancer; 2023 Dec; 153(12):2032-2044. PubMed ID: 37602928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Small Cell and Other Rare Histologic Types of Cervical Cancer.
    Marchocki Z; Swift B; Covens A
    Curr Oncol Rep; 2022 Nov; 24(11):1531-1539. PubMed ID: 35947285
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.
    Parkes EE; Kennedy RD
    Oncologist; 2016 May; 21(5):586-93. PubMed ID: 27022037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current management of ovarian carcinosarcoma.
    Mano MS; Rosa DD; Azambuja E; Ismael G; Braga S; D'Hondt V; Piccart M; Awada A
    Int J Gynecol Cancer; 2007; 17(2):316-24. PubMed ID: 17362309
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Platinum, anthracycline, and alkylating agent-based chemotherapy for ovarian carcinosarcoma.
    Signorelli M; Chiappa V; Minig L; Fruscio R; Perego P; Caspani G; Battistello M; Colombo N
    Int J Gynecol Cancer; 2009 Aug; 19(6):1142-6. PubMed ID: 19820383
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patterns of care, predictors and outcomes of chemotherapy for ovarian carcinosarcoma: A National Cancer Database analysis.
    Rauh-Hain JA; Gonzalez R; Bregar AJ; Clemmer J; Hernández-Blanquisett A; Clark RM; Schorge JO; Del Carmen MG
    Gynecol Oncol; 2016 Jul; 142(1):38-43. PubMed ID: 27107722
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plectin-targeted liposomes enhance the therapeutic efficacy of a PARP inhibitor in the treatment of ovarian cancer.
    Dasa SSK; Diakova G; Suzuki R; Mills AM; Gutknecht MF; Klibanov AL; Slack-Davis JK; Kelly KA
    Theranostics; 2018; 8(10):2782-2798. PubMed ID: 29774075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Abnormalities of DNA repair and gynecological cancers].
    Auguste A; Leary A
    Bull Cancer; 2017 Nov; 104(11):971-980. PubMed ID: 29054544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Poly (ADP-ribose) polymerase inhibitors in the management of ovarian cancer.
    Markman M
    Womens Health (Lond); 2018; 14():1745505717750694. PubMed ID: 29313444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.